These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1199 related items for PubMed ID: 23932783

  • 1. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA.
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 5. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML, van Asseldonk DP, de Boer NK, Losekoot N, Smid K, Mulder CJ, Bouma G, Peters GJ, van Bodegraven AA.
    J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
    Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM.
    Clin Gastroenterol Hepatol; 2004 May; 2(5):410-7. PubMed ID: 15118980
    [Abstract] [Full Text] [Related]

  • 11. Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients.
    Liu Q, Wang Y, Mei Q, Han W, Hu J, Hu N.
    Scand J Gastroenterol; 2016 Sep; 51(9):1093-9. PubMed ID: 27152547
    [Abstract] [Full Text] [Related]

  • 12. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [Abstract] [Full Text] [Related]

  • 13. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
    de Graaf P, de Boer NK, Wong DR, Karner S, Jharap B, Hooymans PM, Veldkamp AI, Mulder CJ, van Bodegraven AA, Schwab M.
    Br J Pharmacol; 2010 Jul; 160(5):1083-91. PubMed ID: 20590602
    [Abstract] [Full Text] [Related]

  • 14. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH, Huang M, Hu PJ.
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [Abstract] [Full Text] [Related]

  • 15. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G, Cuzzoni E, De Iudicibus S, Favretto D, Malusà N, Martelossi S, Pozzi E, Lionetti P, Ventura A, Decorti G.
    World J Gastroenterol; 2015 Mar 28; 21(12):3571-8. PubMed ID: 25834322
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA, Dutch Initiative on Crohn and Colitis.
    Gut; 2014 Mar 28; 63(3):451-7. PubMed ID: 23424097
    [Abstract] [Full Text] [Related]

  • 18. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.
    de Boer NK, Derijks LJ, Keizer-Garritsen JJ, Lambooy LH, Ruitenbeek W, Hooymans PM, van Bodegraven AA, de Jong DJ.
    J Clin Pharmacol; 2007 Feb 28; 47(2):187-91. PubMed ID: 17244769
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.